Brief: Ensysce Biosciences And Quotient Sciences Announce A Partnership On Development And Clinical Testing Of Pf614-Mpar
31/08/2022 18:38
Aug 31 (Reuters) - Ensysce Biosciences Inc ENSC.O :
* ENSYSCE BIOSCIENCES AND QUOTIENT SCIENCES ANNOUNCE A
PARTNERSHIP
ON DEVELOPMENT AND CLINICAL TESTING OF ENSYSCE'S PF614-MPAR, A
NOVEL OPIOID DESIGNED TO PREVENT ABUSE AND OVERDOSE
Source text for Eikon: ID:nPrekKfyxa
Further company coverage: ENSC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ensysce Biosciences
See all newsEnsysce Biosciences Q2 net loss widens on higher R&D costs
Ensysce Biosciences Inc expected to post a loss of 50 cents a share - Earnings Preview
NASDAQ RESUMED AT 09:47 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:42 AM
Brief: Ensysce Biosciences Launches Formal Review Of Strategic Alternatives - SEC Filing